Meet Galen's senior leadership team, responsible for the strategic direction and growth of the organisation at every level and region of our business. They are committed to customer care and empowering Galen employees to deliver extraordinary service every day, to benefit the health of all generations, today and in the future.

Dr Dennise Broderick, Managing Director and President

Dr Dennise Broderick, Managing Director and President

  • Joined Galen: 2018
  • Based in: Craigavon, Northern Ireland
  • Role in the team: Together with Almac Group’s Board of Directors, Dennise is responsible for all aspects of the pharmaceutical company’s operations, marketing and governance across its sites throughout the UK and Europe.
  • Experience: Dennise is a highly successful, respected, and inspiring Executive Business Leader, with an extensive career within the pharmaceutical industry including CEO/MD and senior leadership roles with Pfizer, Hospira, Zeneus and Viatris both in Ireland and Europe. Most recently Dennise held the position of Country Manager, leading the Irish affiliate of IPSEN Pharmaceuticals and was responsible for all aspects of the business. 

Q: What makes Galen extraordinary?

A: We care. Our people are deeply commited to what we as a business are trying to achieve, and also facilitate our partners in achieving their visions too. With a mix of different backgrounds and diverse experience across the team, our people bring their unique perspectives and passion to everything we do. 

Martin Smith, Vice President, Finance

Martin Smith, Vice President, Finance

  • Joined Galen in: 2004
  • Based in: Craigavon, Northern Ireland
  • Role in team: Martin is responsible for overseeing and developing the financial and operational aspects of the global Galen organisation as well as having involvement in key business projects as a member of the Galen Leadership Team.
  • Experience in the industry: With over 20 years’ experience in finance, Martin spent 10 years in the retail and energy sectors before moving into pharma. Since joining Galen in 2004, Martin has been pivotal to the management of our financial success, having progressed from management account to company accountant, and then financial controller before taking up his role of VP of Finance.

Q: What do you feel is the biggest strength of the company right now? 

A: Our resilience. We have a 'never give up' attitude and continue to adapt to the ever-changing market and landscape. 

Simon Lawrence, Commercial Director, Nordics

Simon Lawrence, Commercial Director, Nordics

  • Joined Galen in: 1986
  • Based in: Copenhagen, Denmark,
  • Role in team: Simon has responsibility for leading commercial activities across the Nordic region, including management of sales and marketing activities and supply chain/logistics.
  • Experience: Simon has been with Galen for over 35 years and held a number of senior sales and marketing positions including business development where he was responsible for the strategic identification, evaluation & delivery of growth opportunities, such as in-licensing of new products & expansion to new international markets.

Q: What motivates you to achieve Galen's vision?

A: Knowing that we are creating something that will have a positive and lasting impact on peoples lives and carry on Galen's legacy.

Paul Herrington, Commercial Director UK & Ireland

Paul Herrington, Commercial Director UK & Ireland

  • Joined Galen in: 2020
  • Based in: Craigavon, Northern Ireland
  • Role in team: Paul has responsibility for leading sales and marketing activities across the UK and Ireland, with a particular focus on positioning Penthrox as the number one analgesic in emergency departments and ensuring Galen’s Trustsaver brands provide a cost-effective solution for the UK and Ireland health service.
  • Experience: With over 30 years’ experience in the industry, Paul has previously held a variety of roles across sales, marketing and training in a range of well-known organisations including ICI, AstraZeneca, Novartis, Napp and Consilient Health.

Q: What do you think is the next big trend in the field?

A: Sustainability and building a greener pharmaceutical industry. This is something which is front of mind as we develop new products and add to our portolfio. Galen's vision is to benefit the health of all generations and key to this is the overall health of our planet.

Johnny McGaughey, Head of Business Development

Johnny McGaughey, Head of Business Development

  • Joined Galen in: 2019
  • Based in: Craigavon, Northern Ireland
  • Role in team: Johnny is responsible for the strategic identification, evaluation & delivery of growth opportunities, such as acquisitions, in-licensing of new products, out-licensing of Galen’s products as well as expansion into new international markets. In addition, Johnny oversees the alliance management function within Galen.
  • Experience: Johnny has 18 years’ experience in the industry, previously working in both operational and business development roles within contract research and pharmaceutical companies.

Q: What are your immediate objectives? 

A: Our expansion plans into Northern Europe is a key focus, as well as our organic growth through R&D projects and new product development coming this year.

Louise Mulholland, Head of Commercial Operations

Louise Mulholland, Head of Commercial Operations

  • Joined Galen in: 1995
  • Based in: Craigavon, Northern Ireland,
  • Role in team: Louise is responsible for commercial operations across the Galen business globally. This includes achieving business targets for all products by supporting the sales and marketing divisions, driving sales of non-promoted portfolio products, and being responsible for logistics and supply across all Galen sites and distribution partners.
  • Experience: Louise has worked in Galen for over 25 years in various roles starting out in accounts receivable and went on to manage this team, before spending time in the sales and then progressing to her current role as Head of Commercial Operations.

Q: What do you see are the biggest challenges facing the industry?

A: It is an ever changing landscape with new drugs being developed and regulatory approvals becoming stricter. For operations, the scarcity of active pharmaceutical ingredients for basic drugs is the most challenging and so as a team we are continually working to mitigate any supply chain problems for our patients and customers.

Would you like to discuss how Galen can help you?

If you would like to explore how our expertise could add value to your product, or for an initial discussion about partnering with us, please contact our team.